Order Article Reprints

Battaglia G, Lazzarotto D, Tanasi I, Gurrieri C, Forlani L, Mauro E, Capraro F, Ciotti G, De Bellis E, Callegari C, et al. New Combination Regimens vs. Fludarabine, Cytarabine, and Idarubicin in the Treatment of Intermediate- or Low-Risk Nucleophosmin-1-Mutated Acute Myeloid Leukemia: A Retrospective Analysis from 7 Italian Centers. Journal of Clinical Medicine. 2025; 14(3):700. https://doi.org/10.3390/jcm14030700

Battaglia, Giulia, Davide Lazzarotto, Ilaria Tanasi, Carmela Gurrieri, Laura Forlani, Endri Mauro, Francesca Capraro, Giulia Ciotti, Eleonora De Bellis, Chiara Callegari, and et al. 2025. "New Combination Regimens vs. Fludarabine, Cytarabine, and Idarubicin in the Treatment of Intermediate- or Low-Risk Nucleophosmin-1-Mutated Acute Myeloid Leukemia: A Retrospective Analysis from 7 Italian Centers" Journal of Clinical Medicine 14, no. 3: 700. https://doi.org/10.3390/jcm14030700

Battaglia, G., Lazzarotto, D., Tanasi, I., Gurrieri, C., Forlani, L., Mauro, E., Capraro, F., Ciotti, G., De Bellis, E., Callegari, C., Tosoni, L., Fanin, M., Morelli, G. L., Simio, C., Skert, C., Gottardi, M., Zaja, F., Toffoletti, E., Damiani, D., ... Tiribelli, M. (2025). New Combination Regimens vs. Fludarabine, Cytarabine, and Idarubicin in the Treatment of Intermediate- or Low-Risk Nucleophosmin-1-Mutated Acute Myeloid Leukemia: A Retrospective Analysis from 7 Italian Centers. Journal of Clinical Medicine, 14(3), 700. https://doi.org/10.3390/jcm14030700